Trial Scorecards
Trial Scorecards
October 14, 2019
1 min read
Save

THEMIS

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Researchers evaluated the effect of twice-daily ticagrelor (Brilinta, AstraZeneca) on CV death, MI or stroke in patients with type 2 diabetes.